1.Protection of Saxagliptin for liver inflammatory injury in rat model of diabetes complicating with nonalcoholic fatty liver disease and its mechanism
Huijin LUO ; Yan LIU ; Rongping CHEN ; Shuangshuang ZHANG ; Hong CHEN ; Zhen ZHANG
Chinese Journal of Endocrinology and Metabolism 2015;(6):538-540
[Summary] Thirty-two SD rats were randomly divided into noraml control group(NC, n = 10) and high fat diet group(HF, n=22). 10 weeks later, the HF group rats were injected STZ(30 mg/ kg) to set up the model of diabetes complicating with nonalcoholic fatty liver disease (NAFLD). Then, HF group were randomly divided into model control group(MC, n = 8) and Saxagliptin intervene group( M + S, n = 8). The M + S group were made an intervention with Saxagliptin(10 mg·kg-1 ·d-1 ) for 8 weeks. At the end of 18 weeks, the fasting blood glucose, serum insulin, liver function, liver weight, tumor necrosis factor alpha, and interleukin 6 were measured. HOMA-IR was calculated. Western bolt was used to determine the expression of NF-κB in hepatic tissue. The level of the indexes above increased in the MC group than in the NC group. But the indexes above mentioned in M + S group were ameliorated. The expression of NF-κB was significantly up regulated in MC group as compared with the NC group, and significantly reduced in the M+S group than in the MC group. The results of correlation analysis revealed that TNF-αand IL-6 were positive correlated with HOMR-IR, respectively. Saxagliptin can effectively reduce the blood glucose level and alleviate insulin resistance, then further relieve the inflammation of liver injury, and finally to alleviate the condition of T2DM with NAFLD. It may play a protective role in the damaged hepatic cells.
2.Effect of reduced alpha - cardiac actin 1 gene expression on embryonic cardiomyocytes H9C2 cell apoptosis of rats and its mechanism
Shuangshuang YUAN ; Dongfang SUN ; Meijun XIE ; Binlu ZHU ; Hong JIANG ; Hongkun JIANG
Chinese Journal of Applied Clinical Pediatrics 2018;33(1):58-61
Objective To explore the effect of reduced alpha - cardiac actin 1(ACTC1)gene expression on the rat embryonic cardiomyocytes H9C2 cell apoptosis and its mechanism. Methods The rat embryonic cardiomyocytes H9C2 cell was cultivated;the rat embryonic cardiomyocytes H9C2 cell was transfected with ACTC1 - small interfering RNA(siRNA),and at 24 h,48 h,72 h after transfection,the cells were collected for extraction and purification of RNA, the real - time quantitative PCR(qPCR)method was used to detect the expression level of ACTC1 gene;and the termi-nal deoxynucleotidyl transferase - mediated dUTP - biotin nick end labeling assay(TUNEL)method was used to ex-plore the effect of reduced ACTC1 gene expression on the rat embryonic cardiomyocytes H9C2 cell apoptosis. Western blot was used to detect the expression of Cyto C,cysteine - containing aspartate - specific proteases(Caspase)- 3, Caspase - 8,Caspase - 9,Bcl - 2 and Bax. Results The expression of ACTC1 mRNA detected by qPCR decreased compared with that of the scramble siRNA group in 24 h,48 h,72 h(0. 80 vs. 1. 00,0. 20 vs. 1. 00,0. 25 vs. 1. 00),and in the ACTC1 - siRNA group decreased significantly at 48 h,72 h,and the difference was statistically significant(t =4. 245,P < 0. 05);TUNEL positive cells rate significantly increased in the ACTC1 - siRNA group(80%)compared with that in the scramble siRNA group(20%),and the difference was statistically significant(P < 0. 05);Western blot also confirmed that the expression of Caspase - 3,Caspase - 9,Cyto C and Bax/ Bcl - 2 were accordingly increased (0. 91 ± 0. 12 vs. 0. 59 ± 0. 01,0. 48 ± 0. 09 vs. 0. 24 ± 0. 03,0. 92 ± 0. 03 vs. 0. 45 ± 0. 01,2. 25 ± 0. 26 vs. 1. 16 ± 0. 12),and the differences were statistically significant(t = 2. 821,7. 336,2. 420,0. 798,all P < 0. 05);but the expre-ssion of Caspase - 8 had no obvious change,and the difference was not statistically significant (P > 0. 05 ). Conclusions Reduced ACTC1 gene expression can induce the rat embryonic cardiomyocytes H9C2 cell apoptosis perhaps mainly through endogenous mitochondrial signal transduction pathways.
3.Prenatal diagnosis of women with an adverse reproductive history using both traditional karyotyping and SNP-array
Hongsheng YU ; Hong GUO ; Shuangshuang SHEN ; Xiaochun LI ; Liping ZHANG ; Xufei FAN
Chinese Journal of Obstetrics and Gynecology 2018;53(3):155-159
Objective To explore the occurrence of fetal chromosomal abnormalities among pregnant women with an adverse reproductive history using traditional karyotyping and single nucleotide polymorphism microarray(SNP-array)technology.Methods Totally 94 in 2 163(4.35%)cases of singleton pregnant women with an adverse reproductive history were performed amniocentesis in Jinhua Maternal and Child Health Care Hospital from June 2015 to June 2017. Traditional karyotyping and SNP-array were employed simultaneously for prenatal diagnosis,and the detection rates of the two methods were compared. Results All of the 94 specimens were successfully analyzed, 11 cases were found with chromosomal anomaly, the overall detection rate was 11.7%(11/94). Seven (7.4%,7/94) abnormalities cases were detected by karyotyping,and 7(7.4%)by SNP-array.The karyotyping results of trisomy 21,and 45,X and the deletion of chromosome 13 were consistent with SNP-array.Only 3(3.2%,3/94)microdeletion/duplications (the sizes of duplications and deletions were between 422.4-1 708.4 kb)and 1(1/4)loss of heterozygosity were detected by SNP-array,but were missed by karyotyping.Furthermore, 2 cases′copy number variation were found pathogenic gene related, while the other 2 were considered benign or variant of uncertain significance. Four cases(4/7)of abnormalities were detected by karyotyping, while confirmed balanced translocation and inversion by SNP-array.All patients were informed and chosen to continue the pregnancy.Conclusions The rate of abnormal fetal chromosomes in pregnant women with an adverse reproductive history is still high.SNP-array is a new molecular genetic technique,and combined with use of traditional karyotyping,it could improve the detection rate of fetal chromosomal abnormalities and reduce abortion rate, thus providing a basis for genetic counseling and prenatal diagnosis.
4.Effect of edaravone combined with statins on serum homocysteine, C-reactive protein and lipid levels in patients with ischemic stroke
Yunnan LU ; Ye HUA ; Zhiqiang FENG ; Tao MA ; Peicheng HE ; Shuangshuang WU ; Hong XU
Journal of Clinical Medicine in Practice 2017;21(19):27-30
Objective To analyze the effect of edaravone combined with statins on levels of serum homocysteine (Hcy),C-reactive protein (CRP) and total cholesterol (TC),triglyceride (TG),high-density lipoprotein HDL),low-density lipoprotein cholesterol (LDL-C) in patients with ischemic stroke.Methods A total of 63 patients with ischemic stroke in our hospital were divided into two groups,27 cases in control group were given atorvastatin,and 36 patients in the observation group were given edaravone treatment in addition.The levels of Hcy,TG,TC,HDL and low LDL-C were detected.At the same time,stroke scale of NIHSS,Barthel index of daily living ability,Self Anxiety Scale (SAS) and Self Depression Scale (SDS) were recorded at 14 days before and after treatment.Results The observation group had lower Hcy,CRP and LDL-C levels,while higher HDL level.Total effective rate in the observation group was significantly higher than the control group (88.89% vs.77.78%,P <0.05).The observation group had higher Barthel index and lower SAS,SDS scores than the control group (P < 0.05).Conclusion Edaravone combined with atorvastatin can significantly improve patients' treatment outcomes,and improve prognosis and life ability.
5.Effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction
Hong XU ; Ye HUA ; Zhigang FENG ; Shuangshuang WU ; Tao MA ; Yumin LIU ; Yunnan LU
Journal of Clinical Medicine in Practice 2017;21(19):31-33
Objective To observe the effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction and their influence on serum inflammatory factors.Methods A total of 68 patients with acute cerebral infarction were equally divided into observation group and control group by random number table method.All patients were given anti-stroke therapy.Patents in control group were given edaravone,while,patients in observation group were given oxiracetam on the base of control group.Then the clinical efficacy and adverse reactions of two groups were observed.The changes of NIHSS,C-reactive protein (hs-CRP),interleukin-6 (IL-6),tumor necrosis factor (TNF-α) levels were also measured.Results The total effective rate of observation group was 94.12% and 76.47% in the control group.The total effective rate of observation group was higher than control group (P < 0.05).Both the basic cure rate and significant progress rate of observation group were also less than control group (P <0.05).The NIHSS,CRP,IL-6 and TNF-α levels of patients in two group decreased after treatment (P < 0.05),and those indexes of observation group were much lower than that in the control group after treatment (P < 0.05).Conclusion Treatment of oxiracetam combined with edaravone in patients with acute cerebral infarction can reduce the NIHSS and serum CRP,IL-6,TNF-α levels,and improve neurologic impairment.
6.Effects of aspirin combined with clopidogrel on Hcy and hs-CRP in patients with cerebral infarction and analysis prognosis
Zhiqiang FENG ; Yunnan LU ; Hong XU ; Tao MA ; Yumin LIU ; Shuangshuang WU ; Ye HUA
Journal of Clinical Medicine in Practice 2017;21(19):38-40,43
Objective To analyze the effects of aspirin combined with clopidogrel on Hcy and hs-CRP in patients with cerebral infarction.Methods A total of 69 patients with cerebral infarction in our hospital were divided into two groups,patients in observation group with 39 cases were treated with aspirin combined with clopidogrel,and control group with 29 cases treated with aspirin.The therapeutic effects of two groups,the changes of serum Hcy,hs-CRP and NIHSS scores before and after treatment were observed.Results Hcy and hs-CRP levels were significantly decreased in the observation group and the control group after seven days of treatment.However,the observation group was significantly lower.After treatment,NIHSS score decreased in both groups,however,there was no significant difference in NIHSS in two groups.The ESS and ADL score were significantly improved,and observation group was better than the control group after 21 days of treatment(P <0.05).Conclusion Aspirin combined with clopidogrel can significantly reduce serum Hcy and hsCRP levels,and improve the prognosis in patients with cerebral infarction.
7.Effect of edaravone combined with statins on serum homocysteine, C-reactive protein and lipid levels in patients with ischemic stroke
Yunnan LU ; Ye HUA ; Zhiqiang FENG ; Tao MA ; Peicheng HE ; Shuangshuang WU ; Hong XU
Journal of Clinical Medicine in Practice 2017;21(19):27-30
Objective To analyze the effect of edaravone combined with statins on levels of serum homocysteine (Hcy),C-reactive protein (CRP) and total cholesterol (TC),triglyceride (TG),high-density lipoprotein HDL),low-density lipoprotein cholesterol (LDL-C) in patients with ischemic stroke.Methods A total of 63 patients with ischemic stroke in our hospital were divided into two groups,27 cases in control group were given atorvastatin,and 36 patients in the observation group were given edaravone treatment in addition.The levels of Hcy,TG,TC,HDL and low LDL-C were detected.At the same time,stroke scale of NIHSS,Barthel index of daily living ability,Self Anxiety Scale (SAS) and Self Depression Scale (SDS) were recorded at 14 days before and after treatment.Results The observation group had lower Hcy,CRP and LDL-C levels,while higher HDL level.Total effective rate in the observation group was significantly higher than the control group (88.89% vs.77.78%,P <0.05).The observation group had higher Barthel index and lower SAS,SDS scores than the control group (P < 0.05).Conclusion Edaravone combined with atorvastatin can significantly improve patients' treatment outcomes,and improve prognosis and life ability.
8.Effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction
Hong XU ; Ye HUA ; Zhigang FENG ; Shuangshuang WU ; Tao MA ; Yumin LIU ; Yunnan LU
Journal of Clinical Medicine in Practice 2017;21(19):31-33
Objective To observe the effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction and their influence on serum inflammatory factors.Methods A total of 68 patients with acute cerebral infarction were equally divided into observation group and control group by random number table method.All patients were given anti-stroke therapy.Patents in control group were given edaravone,while,patients in observation group were given oxiracetam on the base of control group.Then the clinical efficacy and adverse reactions of two groups were observed.The changes of NIHSS,C-reactive protein (hs-CRP),interleukin-6 (IL-6),tumor necrosis factor (TNF-α) levels were also measured.Results The total effective rate of observation group was 94.12% and 76.47% in the control group.The total effective rate of observation group was higher than control group (P < 0.05).Both the basic cure rate and significant progress rate of observation group were also less than control group (P <0.05).The NIHSS,CRP,IL-6 and TNF-α levels of patients in two group decreased after treatment (P < 0.05),and those indexes of observation group were much lower than that in the control group after treatment (P < 0.05).Conclusion Treatment of oxiracetam combined with edaravone in patients with acute cerebral infarction can reduce the NIHSS and serum CRP,IL-6,TNF-α levels,and improve neurologic impairment.
9.Effects of aspirin combined with clopidogrel on Hcy and hs-CRP in patients with cerebral infarction and analysis prognosis
Zhiqiang FENG ; Yunnan LU ; Hong XU ; Tao MA ; Yumin LIU ; Shuangshuang WU ; Ye HUA
Journal of Clinical Medicine in Practice 2017;21(19):38-40,43
Objective To analyze the effects of aspirin combined with clopidogrel on Hcy and hs-CRP in patients with cerebral infarction.Methods A total of 69 patients with cerebral infarction in our hospital were divided into two groups,patients in observation group with 39 cases were treated with aspirin combined with clopidogrel,and control group with 29 cases treated with aspirin.The therapeutic effects of two groups,the changes of serum Hcy,hs-CRP and NIHSS scores before and after treatment were observed.Results Hcy and hs-CRP levels were significantly decreased in the observation group and the control group after seven days of treatment.However,the observation group was significantly lower.After treatment,NIHSS score decreased in both groups,however,there was no significant difference in NIHSS in two groups.The ESS and ADL score were significantly improved,and observation group was better than the control group after 21 days of treatment(P <0.05).Conclusion Aspirin combined with clopidogrel can significantly reduce serum Hcy and hsCRP levels,and improve the prognosis in patients with cerebral infarction.
10.Efficacy of a skin care ointment containing oligomeric maltose X in the adjuvant treatment of pruritus in patients with mild to moderate eczema: a multicenter, randomized, double-blind controlled clinical study
Yan LI ; Lujing XIANG ; Ming LI ; Mingjun LEI ; Zan TIAN ; Jianguo YUAN ; Hong ZHOU ; Ying LIU ; Jie WANG ; Jinguang CHEN ; Ting WANG ; Shuangshuang GAO ; Yu ZHANG ; Linfeng LI
Chinese Journal of Dermatology 2022;55(11):1021-1025
Objective:To evaluate the clinical efficacy and safety of a skin care ointment containing oligomeric maltose X in the adjuvant treatment of eczema-related pruritus.Methods:A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted. From March to September 2021, outpatients with mild to moderate eczema were collected from departments of dermatology of 4 hospitals, including Beijing Friendship Hospital, Hebei Traditional Chinese Medical Hospital, the Third People′s Hospital of Hubei Province, and Taizhou Central Hospital in Zhejiang Province. The patients were randomly divided into two groups by using a random number table: observation group topically treated with a skin care ointment containing oligomeric maltose X, and vehicle control group topically treated with an ointment vehicle. The ointments were applied during the attacks of itching for 14 consecutive days. Visits were scheduled before, 7, and 14 days after the start of the adjuvant treatment. The efficacy was evaluated according to the eczema area and severity index (EASI) and visual analog scale (VAS) , and adverse events were recorded. The efficacy and safety analyses were conducted by using chi-square test and t test. Results:Totally, 232 patients with eczema were enrolled, including 90 males and 142 females, with the age being 40.13 ± 13.36 years; 156 patients were in the observation group, and 76 in the vehicle control group. Before the adjuvant treatment, there were no significant differences in EASI (2.07 ± 2.24 points vs. 2.29 ± 2.28 points) or VAS (6.22 ± 1.78 points vs. 6.20 ± 1.79 points) scores between the observation group and vehicle control group ( t = -0.70, 0.06, P = 0.486, 0.955, respectively) . After one-day treatment, the VAS scores significantly decreased compared with the baseline scores in the two groups ( P < 0.001, P = 0.003, respectively) . After 14-day treatment, the VAS score was significantly lower in the observation group (2.67 points) than in the vehicle control group (3.35 points; t = -2.28, P = 0.024) . After 7- and 14-day treatment, the EASI scores significantly decreased compared with the baseline scores in both the two groups (all P < 0.001) , but there were no significant differences between the two groups ( P = 0.853, 0.731) . No adjuvant treatment-related adverse events were recorded in either of the two groups. Conclusion:The skin care ointment containing oligomeric maltose X is safe and effective in the adjuvant treatment of eczema-related pruritus, and can be applied to clinical practice.